Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 7/20 | 0.77 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.64 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.41 |
| ▸ | MPO | P05164 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metaglidasen SCHEMBL14606136 | 0.87 | PPARG (1.00) | PPARGSLC22A12PPARAP2RY1SLC6A9 | |
| Metaglidasen SCHEMBL29387584 | 0.87 | PPARG (1.00) | PPARGSLC22A12PPARAP2RY1SLC6A9 | |
| Mbx-102 Acid Form SCHEMBL12189837 | 0.87 | PPARG (1.00) | PPARGSLC22A12PPARAP2RY1SLC6A9 | |
| Metaglidasen SCHEMBL2443233 | 0.87 | PPARG (1.00) | PPARGSLC22A12PPARAP2RY1SLC6A9 | |
| SCHEMBL14541455 | 0.86 | PPARG (0.75) | PPARGSLC22A12PPARAP2RY1ALDH1A1 | |
| SCHEMBL2443487 | 0.86 | PPARG (0.75) | PPARGSLC22A12PPARAP2RY1ALDH1A1 | |
| SCHEMBL13374098 | 0.86 | PPARG (0.71) | PPARGSLC22A12PPARAALDH1A1HPGD | |
| Metaglidasen SCHEMBL11733289 | 0.86 | PPARG (0.97) | PPARGSLC22A12PPARAP2RY1SLC6A9 | |
| SCHEMBL2450141 | 0.85 | PPARG (0.81) | PPARGSLC22A12PPARAP2RY1ALDH1A1 | |
| SCHEMBL12189841 | 0.85 | PPARG (0.81) | PPARGSLC22A12PPARAP2RY1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343493-B1 | USE OF(-) (3-HALOMETHYLPHENOXY) (4-HALOPHENYL) ACETIC ACID DERIVATIVES FOR TREATMENT OF INSULIN RESISTANCE, TYPE 2 DIABETES AND HYPERURICEMIA | METABOLEX INC (US) | 2012-10-31 | — | — | EP | disclosed |
| US-8288438-B2 | Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer | METABOLEX, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-8288438-B2 | Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer | METABOLEX, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20080269189-A1 | Method for Avoiding Edema in the Treatment or Prevention of Ppary-Responsive Diseases, Including Cancer | DIATEX, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080269189-A1 | Method for Avoiding Edema in the Treatment or Prevention of Ppary-Responsive Diseases, Including Cancer | DIATEX, INC. | 2008-10-30 | — | — | US | disclosed |
| US-20080194646-A1 | Methods For Avoiding Edema in the Treatment of Metabolic, Inflammatory, and Cardiovascular Disorders | DIATEX, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194646-A1 | Methods For Avoiding Edema in the Treatment of Metabolic, Inflammatory, and Cardiovascular Disorders | DIATEX, INC. | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269189-A1 | Method for Avoiding Edema in the Treatment or Prevention of Ppary-Responsive Diseases, Including Cancer | PPARG, PPARA, PPARD | PPARG 1/4885SLC22A12 960/4885PPARA 2/4885 |
| US-20080194646-A1 | Methods For Avoiding Edema in the Treatment of Metabolic, Inflammatory, and Cardiovascular Disorders | PPARG, PPARA, PPARD | PPARG 1/4885SLC22A12 1113/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.